Skip to contentpdufa.bio

IM-1021 Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

IM-1021 Phase is an Immunome, Inc. program in oncology (hematologic; ASH dataset). Its next catalyst is a Readout on Dec 14, 2026.

IMNM catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: oncology (hematologic; ASH dataset). Sponsor: Immunome, Inc. (IMNM). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 14, 2026IMNM

Specialist biotech funds holding IMNM, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Redmile Group4,363,064$93.8 millionfiled November 16, 2026
Baker Bros. Advisors55,306$1.2 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is IM-1021 Phase's next FDA decision or readout?

The next tracked catalyst for IM-1021 Phase is a Readout on Dec 14, 2026.

What happened at IM-1021 Phase's most recent FDA decision?

No FDA decision for IM-1021 Phase is in our archive yet.

What is IM-1021 Phase used for?

In our records IM-1021 Phase is under review or in development for oncology (hematologic; ASH dataset).

Who makes IM-1021 Phase?

Immunome, Inc. (IMNM).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.